Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992392 | 1.00 | CETP (0.89) | CETP | |
| SCHEMBL14597747 | 0.94 | CETP (0.88) | CETP | |
| SCHEMBL992972 | 0.94 | CETP (0.88) | CETP | |
| SCHEMBL5466271 | 0.94 | CETP (0.88) | CETP | |
| Torcetrapib SCHEMBL29403162 | 0.94 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL10041443 | 0.94 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL49081 | 0.94 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL7169875 | 0.94 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL126708 | 0.94 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL6277910 | 0.94 | CETP (1.00) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453544-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-2258352-B1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | BEND RES INC (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2258352-A2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | Bend Research, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-1607389-A1 | 4-protected-amino-2-substituted-1,2,3,4-tetrahydroquinolines as intermediates for CETP inhibitors | Pfizer Products Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-6962931-B2 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1581210-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1114031-B1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6906082-B2 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | PFIZER INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1453544-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004056359-A1 | DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040092550-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. | 2004-02-26 | — | — | US | disclosed |
| US-6586448-B1 | Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2003000295-A2 | SELF-EMULSIFYING FORMULATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-1199071-A2 | Use of an estrogen agonist/antagonist for improving vascular health | Pfizer Products Inc. (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092550-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | CETP, APOB, NR1H2 | CETP 1/4885 |
| US-20030022944-A1 | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | CETP, LCAT, LIPA | CETP 1/4885 |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | CETP, MTTP, APOB | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.